This review mainly focuses on the physiological function of 4-hydroxyphenylpyruvate dioxygenase (HPPD), as well as on the development and application of HPPD inhibitors of several structural classes. Among them, one illustrative example is represented by compounds belonging to the class of triketone compounds. They were discovered by serendipitous observations on weed growth and were developed as bleaching herbicides. Informed reasoning on nitisinone (NTBC, 14), a triketone that failed to reach the final steps of the herbicidal design and development process, allowed it to become a curative agent for type I tyrosinemia (T1T) and to enter clinical trials for alkaptonuria. These results boosted the research of new compounds able to interfere with HPPD activity to be used for the treatment of the tyrosine metabolism-related diseases.
Santucci, A., Bernardini, G., Braconi, D., Petricci, E., Manetti, F. (2017). 4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases. JOURNAL OF MEDICINAL CHEMISTRY, 60(10), 4101-4125 [10.1021/acs.jmedchem.6b01395].
4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases
SANTUCCI, ANNALISA;BERNARDINI, GIULIA;BRACONI, DANIELA;PETRICCI, ELENA;MANETTI, FABRIZIO
2017-01-01
Abstract
This review mainly focuses on the physiological function of 4-hydroxyphenylpyruvate dioxygenase (HPPD), as well as on the development and application of HPPD inhibitors of several structural classes. Among them, one illustrative example is represented by compounds belonging to the class of triketone compounds. They were discovered by serendipitous observations on weed growth and were developed as bleaching herbicides. Informed reasoning on nitisinone (NTBC, 14), a triketone that failed to reach the final steps of the herbicidal design and development process, allowed it to become a curative agent for type I tyrosinemia (T1T) and to enter clinical trials for alkaptonuria. These results boosted the research of new compounds able to interfere with HPPD activity to be used for the treatment of the tyrosine metabolism-related diseases.
| File | Dimensione | Formato | |
|---|---|---|---|
|
2017JMedChem_HPPD_inhibitors.pdf
non disponibili
Tipologia:
PDF editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
4.21 MB
Formato
Adobe PDF
|
4.21 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
BRACONI-4-hydroxy-POST-PRINT.pdf
accesso aperto
Descrizione: Post-Print
Tipologia:
Post-print
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
1.5 MB
Formato
Adobe PDF
|
1.5 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1006035